intermediate-grade DCIS was met. The study population included 565 women with low- or intermediate-grade DCIS and 105 women with high-grade DCIS. Approximately 30% of women in each group took tamoxifen for some time. After a median follow-up of more than 6
Search Results
Risk Reduction Strategies for Ductal Carcinoma In Situ
Adam L. Cohen and John H. Ward
Breast Cancer Risk Reduction
Therese B. Bevers, Deborah K. Armstrong, Banu Arun, Robert W. Carlson, Kenneth H. Cowan, Mary B. Daly, Irvin Fleming, Judy E. Garber, Mary Gemignani, William J. Gradishar, Helen Krontiras, Swati Kulkarni, Christine Laronga, Loretta Loftus, Deborah J. MacDonald, Martin C. Mahoney, Sofia D. Merajver, Ingrid Meszoely, Lisa Newman, Elizabeth Pritchard, Victoria Seewaldt, Rena V. Sellin, Charles L. Shapiro, and John H. Ward
reduction agents/strategies, such as tamoxifen, raloxifene, and risk reduction surgery, have been identified. However, women and their physicians who are considering interventions to reduce risk for breast cancer must balance the demonstrated benefits with
Predictors and Temporal Trends of Adjuvant Aromatase Inhibitor Use in Breast Cancer
Tiffany H. Svahn, Joyce C. Niland, Robert W. Carlson, Melissa E. Hughes, Rebecca A. Ottesen, Richard L. Theriault, Stephen B. Edge, Anne F. Schott, Michael A. Bookman, and Jane C. Weeks
overview of the randomised trials . Lancet 2005 ; 365 : 1687 – 1717 . 2 Baum M . The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women [abstract] . Breast Cancer Res Treat 2001
Pharmacogenetics of Tamoxifen: Who Should Undergo CYP2D6 Genetic Testing?
Michaela J. Higgins, James M. Rae, David A. Flockhart, Daniel F. Hayes, and Vered Stearns
, and side effects . N Engl J Med 2003 ; 348 : 538 – 549 . 5 Desta Z Ward BA Soukhova NV . Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D
Adjuvant Endocrine Therapy in Hormone Receptor-Positive Postmenopausal Breast Cancer: Evolution of NCCN, ASCO, and St Gallen Recommendations
Robert W. Carlson, Clifford A. Hudis, and Kathy I. Pritchard
early breast cancer . Oncology (Williston Park) 2005 ; 19 : 1425 – 1428 , 1433 . 2. Osborne CK . Tamoxifen in the treatment of breast cancer . N Engl J Med 1998 ; 339 : 1609 – 1618 . 3. Field MJ Lohr KN , eds. Clinical
Nonhormonal Management of Hot Flashes for Women on Risk Reduction Therapy
Kostandinos Sideras and Charles L. Loprinzi
cancer risk reduction be discussed and considered as an option for women with increased risk of developing breast cancer. 6 , 7 For postmenopausal women, the currently approved agents are tamoxifen and raloxifene, both recommended for a maximum of 5
Breast Cancer Risk Reduction and Counseling: Lifestyle, Chemoprevention, and Surgery
Martin C. Mahoney
cancer risk: estrogen versus estrogen plus progestin . J Natl Cancer Inst 2000 ; 92 : 328 – 332 . 22. Fisher B Costantino JP Wickerham DL . Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel
Breast Cancer: Noninvasive and Special Situations
Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Neal S. Topham, John H. Ward, Eric P. Winer, and Antonio C. Wolff
tamoxifen given for 5 years is associated with an approximately 46% reduction (hazard ratio, 0.54; 95% CI, 0.27–1.02) in the risk of developing invasive breast cancer among women with LCIS. 37 , 38 Results from the NSABP Study of Tamoxifen and Raloxifene
Optimizing Endocrine Therapy for Breast Cancer
Amelia B. Zelnak and Ruth M. O'Regan
endocrine therapy, or how long this treatment should be given. Whether a subset of premenopausal women with HR-positive early-stage breast cancer should receive ovarian ablation in combination with tamoxifen remains unclear. In the metastatic setting
Costs and Benefits of Extended Endocrine Strategies for Premenopausal Breast Cancer
Janice S. Kwon, Gary Pansegrau, Melica Nourmoussavi, Geoffrey L. Hammond, and Mark S. Carey
Background Recent evidence suggests that extending endocrine therapy for another 5 years after the initial 5 years of tamoxifen is beneficial for premenopausal women with estrogen receptor (ER)–positive breast cancer. In the ATLAS (Adjuvant
